ALS Patient-derived iPSC Models for Advancing Drug Discovery

Time: 2:00 pm
day: Conference Day One Track A PM

Details:

  • Development of targeted disease modifying therapeuticsDevelopment of multiple neuronal & glial cell types from healthy and disease patient iPSC lines
  • TDP43 mislocalization in ALS-patient iPSC derived motor neuron
  • Current capabilities and potential future applications in advancing personalized medicine for ALS disease & other neurodegenerative diseases
  • Demonstrating how these models improve target discovery, biomarker validation, and preclinical predictability in drug development

Speakers:

Tetsuya Tanaka